Related Experiment Video

Updated: Jun 29, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Protein Tyrosine Phosphatase PRL-3: A Key Player in Cancer Signaling

Haidong Liu1,2, Xiao Li3, Yin Shi4

  • 1Zhejiang Cancer Hospital, Hangzhou 310022, China.

Biomolecules
|March 28, 2024
PubMed

Insights

Phosphatase of regenerating liver-3 (PRL-3) is a key phosphatase in cancer progression, influencing multiple cellular processes. Research is advancing targeted therapies, including small molecule inhibitors and antibodies, for effective cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Protein phosphatases regulate signal transduction via dephosphorylation.
  • Phosphatase of regenerating liver-3 (PRL-3) is a dual-specific phosphatase linked to cancer development.
  • Targeting PRL-3 is critical for novel cancer therapies.

Purpose of the Study:

  • To review PRL-3's regulatory mechanisms, expression, and roles in cancer.
  • To summarize PRL-3's involvement in proliferation, migration, invasion, metastasis, angiogenesis, and drug resistance.
  • To discuss the progress of therapeutic inhibitors and the prognostic value of PRL-3.

Main Methods:

  • Literature review of PRL-3's function in cancer.
  • Analysis of regulatory mechanisms including transcriptional control, alternative splicing, and post-translational modifications.
  • Evaluation of PRL-3's expression patterns in various cancer types.

Main Results:

  • PRL-3 significantly contributes to cancer progression through multiple cellular functions.
  • Specific expression patterns of PRL-3 in certain cancers suggest therapeutic potential.
  • Small molecule inhibitors and the antibody PRL-3-zumab show promise in preclinical and clinical studies.

Conclusions:

  • PRL-3 is a crucial target for cancer therapy due to its multifaceted roles.
  • Further research is needed to optimize PRL-3 inhibitors for clinical application.
  • PRL-3-zumab represents a promising therapeutic strategy in ongoing clinical trials.
Keywords:
cancerdrug resistancephosphatase of regenerating liver-3 (PRL-3)protein phosphatases

More Related Videos

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

2.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

83

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K